Skip to content

A cluster randomized controlled trial of Uyghur medicine combined with carpotriol ointment in the treatment of mild to moderate psoriasis vulgaris

Study on key technologies and regimen of Uyghur medicine for the prevention and treatment of psoriasis vulgaris

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2023000042
Enrollment
Unknown
Registered
2023-09-04
Start date
2023-09-09
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis vulgaris

Interventions

Combined treatment group:Uyghur medicine and carpotriol ointment

Sponsors

Hospital of Xinjiang Traditional Uyghur Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients with mild to moderate psoriasis vulgaris according to the diagnostic criteria. (2) PASI score<10 points, BSA<10%, DLQI<10 points. (3) According to the analysis of Uyghur medicine differentiation, patients with psoriasis vulgaris who meet the diagnosis of salty mucus. (4) Age range from 18 to 65 years old. (5) Informed consent, voluntary testing

Exclusion criteria

Exclusion criteria: (1) Tuberculosis and tumor patients. (2) Combined with severe cardiac insufficiency, severe primary diseases such as liver and kidney systems. (Note: ALT and AST exceed the upper limit of the normal range by 2 times, while Cr exceeds the upper limit of the normal range.) (3) Have taken steroids or any medication to treat psoriasis within the past 2 weeks; Have taken retinoic acid drugs or topical steroid preparations and any topical medication for the treatment of psoriasis within one week. (4) Plan for pregnant, pregnant, or lactating women. (5) Suspected or confirmed history of alcohol or drug abuse. (6) Allergic constitution (allergic to two or more other drugs), or allergic to the drug components in this plan. (7) Other situations that may reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the work environment, mental disorders, communication difficulties, etc., are deemed unsuitable by the researchers to participate in this clinical trial. (8) Individuals who have participated in clinical trials of other drugs within the past month or are currently participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
psoriasis area and severity index,PASI;

Secondary

MeasureTime frame
Uyghur Medical Syndrome Score;Post effect of 18 weeks;Dermatology Life Quality Index, DLQI;Affected area of body surface,BSA;

Countries

China

Contacts

Public ContactZaytungul Hufur

Hospital of Xinjiang Traditional Uyghur Medicine

18999977049m@sina.cn18999977049

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026